DK1377298T3 - Exemestan til behandling af hormon-afhængige lidelser - Google Patents
Exemestan til behandling af hormon-afhængige lidelserInfo
- Publication number
- DK1377298T3 DK1377298T3 DK02727314T DK02727314T DK1377298T3 DK 1377298 T3 DK1377298 T3 DK 1377298T3 DK 02727314 T DK02727314 T DK 02727314T DK 02727314 T DK02727314 T DK 02727314T DK 1377298 T3 DK1377298 T3 DK 1377298T3
- Authority
- DK
- Denmark
- Prior art keywords
- exemestane
- hormone
- treatment
- dependent disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77091101A | 2001-01-26 | 2001-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1377298T3 true DK1377298T3 (da) | 2007-01-02 |
Family
ID=25090093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02727314T DK1377298T3 (da) | 2001-01-26 | 2002-01-18 | Exemestan til behandling af hormon-afhængige lidelser |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1377298B1 (fr) |
JP (1) | JP2004519490A (fr) |
AR (1) | AR032268A1 (fr) |
AT (1) | ATE337787T1 (fr) |
CA (1) | CA2434611A1 (fr) |
DE (1) | DE60214355T2 (fr) |
DK (1) | DK1377298T3 (fr) |
ES (1) | ES2269682T3 (fr) |
MX (1) | MXPA03006607A (fr) |
PE (1) | PE20020843A1 (fr) |
PT (1) | PT1377298E (fr) |
WO (1) | WO2002072106A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
WO2003017973A1 (fr) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet |
GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
US20060173062A1 (en) * | 2003-06-20 | 2006-08-03 | Boice Judith A | Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
JP5256042B2 (ja) * | 2005-11-22 | 2013-08-07 | インサイト・コーポレイション | 癌の処置のための併用療法 |
KR20150050595A (ko) | 2006-03-28 | 2015-05-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
WO2008019048A1 (fr) * | 2006-08-04 | 2008-02-14 | Meditrina Pharmaceuticals | Utilisation d'inhibiteurs d'aromatase pour amincir l'endomètre ou traiter la ménorragie |
CN101717393A (zh) * | 2009-12-01 | 2010-06-02 | 陈依军 | 环己基2,5-二取代苯基醚的衍生物及其应用 |
DE102010003494A1 (de) * | 2010-03-31 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
CA2857057A1 (fr) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Modulateurs fluores des recepteurs d'strogenes et leurs utilisations |
EP4249471A3 (fr) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Composition pharmaceutique d'un composé contenant de l'azote ou son sel ou son complexe métallique |
ES2806276T3 (es) | 2015-12-30 | 2021-02-17 | Univ Saint Louis | Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina |
CN113712974A (zh) * | 2021-08-20 | 2021-11-30 | 南京大学 | 阿司匹林在制备治疗子宫内膜增生药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
GB8617107D0 (en) * | 1986-07-14 | 1986-08-20 | Erba Farmitalia | 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives |
NZ261123A (en) * | 1993-02-18 | 1996-08-27 | Erba Carlo Spa | Fluorinated 4-aminoandrostadienone derivatives |
GB9313420D0 (en) * | 1993-06-29 | 1993-08-11 | Erba Carlo Spa | Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations |
JP2002533416A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法 |
PL360153A1 (en) * | 2000-05-15 | 2004-09-06 | Pharmacia & Upjohn S.P.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
AU8986501A (en) * | 2000-09-08 | 2002-03-22 | Pharmacia & Upjohn Spa | Exemestane as chemopreventing agent |
-
2002
- 2002-01-18 DK DK02727314T patent/DK1377298T3/da active
- 2002-01-18 JP JP2002571065A patent/JP2004519490A/ja not_active Withdrawn
- 2002-01-18 DE DE60214355T patent/DE60214355T2/de not_active Expired - Fee Related
- 2002-01-18 EP EP02727314A patent/EP1377298B1/fr not_active Expired - Lifetime
- 2002-01-18 AT AT02727314T patent/ATE337787T1/de not_active IP Right Cessation
- 2002-01-18 MX MXPA03006607A patent/MXPA03006607A/es not_active Application Discontinuation
- 2002-01-18 WO PCT/EP2002/000638 patent/WO2002072106A2/fr active IP Right Grant
- 2002-01-18 ES ES02727314T patent/ES2269682T3/es not_active Expired - Lifetime
- 2002-01-18 PT PT02727314T patent/PT1377298E/pt unknown
- 2002-01-18 CA CA002434611A patent/CA2434611A1/fr not_active Abandoned
- 2002-01-23 PE PE2002000050A patent/PE20020843A1/es not_active Application Discontinuation
- 2002-01-24 AR ARP020100236A patent/AR032268A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1377298A2 (fr) | 2004-01-07 |
PE20020843A1 (es) | 2002-09-25 |
PT1377298E (pt) | 2006-12-29 |
CA2434611A1 (fr) | 2002-09-19 |
WO2002072106A3 (fr) | 2003-10-30 |
AR032268A1 (es) | 2003-10-29 |
ATE337787T1 (de) | 2006-09-15 |
EP1377298B1 (fr) | 2006-08-30 |
MXPA03006607A (es) | 2003-09-22 |
ES2269682T3 (es) | 2007-04-01 |
JP2004519490A (ja) | 2004-07-02 |
WO2002072106A2 (fr) | 2002-09-19 |
DE60214355D1 (de) | 2006-10-12 |
DE60214355T2 (de) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7099A (is) | Efnasambönd til að meðhöndla bólgutruflanir | |
DK0967214T3 (da) | Intranasale formuleringer til behandling af seksuelle forstyrrelser | |
DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
DK1474416T3 (da) | Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser | |
DK1259512T3 (da) | Pteridinforbindelser til behandling af psoreasis | |
DK1451143T3 (da) | Fremgangsmåder til fremstilling af O-desmethylvenlafaxin | |
DK1427437T3 (da) | Oxyntomodulin til forebyggelse eller behandling af overvægt | |
DK1223927T3 (da) | Anvendelse af retigabin til behandling af neuropatiske smerter | |
DK1147083T3 (da) | Arylpiperazinyl-cyclohexylindolderivater til behandling af depression | |
DK1277722T3 (da) | Fremgangsmåde til fremstilling af methanol | |
DK1711530T3 (da) | Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme | |
DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
DK1143977T3 (da) | 2-oxy-benzoxazinonderivater til behandling af obesitas | |
DK1840125T3 (da) | Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater | |
DK1380121T3 (da) | Fremgangsmåde til fremstilling af oxazolidinoner | |
DK1377298T3 (da) | Exemestan til behandling af hormon-afhængige lidelser | |
DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
DK1491212T3 (da) | Middel til behandling af søvnforstyrrelser | |
DK1407037T3 (da) | Fremgangsmåde til fremstilling af tagatose | |
DK1324970T3 (da) | Retinoider til behandling af emfysem | |
DK1206436T3 (da) | Retinoider til behandling af emfysem | |
DK2189162T3 (da) | Fremgangsmåder til behandling af cellulære proliferative forstyrrelser | |
DK3332789T3 (da) | Cladribinkur til behandling af multipel sklerose | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff |